Cd55-deficient Protein-losing Enteropathy
📧 Sign up to get email alerts when something new happens for Cd55-deficient Protein-losing Enteropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS approval · 2025-11-10Clinical Trial Update: Compassionate Use of Pozelimab
Pozelimab has been approved for marketing for CD55-deficient Protein-losing Enteropathy under compassionate-use provisions.
-
CLINICAL_TRIALS approval · 2025-11-10Clinical Trial Update: Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
Pozelimab has been approved for marketing for CD55-Deficient Protein-Losing Enteropathy.